Sit Investment Associates Inc. Boosts Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Sit Investment Associates Inc. raised its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 22.1% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 44,390 shares of the biotechnology company’s stock after purchasing an additional 8,038 shares during the quarter. Sit Investment Associates Inc.’s holdings in Sarepta Therapeutics were worth $5,397,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Manchester Capital Management LLC grew its holdings in shares of Sarepta Therapeutics by 86.6% in the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 110 shares in the last quarter. MassMutual Private Wealth & Trust FSB grew its stake in shares of Sarepta Therapeutics by 169.6% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock worth $30,000 after buying an additional 156 shares in the last quarter. Sunbelt Securities Inc. increased its holdings in shares of Sarepta Therapeutics by 446.2% in the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock worth $35,000 after buying an additional 232 shares during the last quarter. Newbridge Financial Services Group Inc. purchased a new stake in shares of Sarepta Therapeutics during the 4th quarter valued at about $36,000. Finally, Steward Partners Investment Advisory LLC lifted its holdings in shares of Sarepta Therapeutics by 164.4% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company’s stock valued at $38,000 after acquiring an additional 194 shares during the last quarter. Institutional investors own 86.68% of the company’s stock.

Insider Buying and Selling at Sarepta Therapeutics

In other news, Director Claude Nicaise sold 2,491 shares of the firm’s stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total value of $248,203.24. Following the completion of the sale, the director now owns 27,812 shares of the company’s stock, valued at $2,771,187.68. This trade represents a 8.22 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 7.70% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

SRPT has been the topic of a number of recent research reports. Scotiabank decreased their price objective on Sarepta Therapeutics from $105.00 to $80.00 and set a “sector perform” rating on the stock in a research report on Thursday, March 20th. Deutsche Bank Aktiengesellschaft lowered their price target on Sarepta Therapeutics from $124.00 to $99.00 and set a “hold” rating for the company in a research report on Wednesday, March 19th. Royal Bank of Canada cut shares of Sarepta Therapeutics from an “outperform” rating to a “sector perform” rating and cut their price objective for the company from $161.00 to $87.00 in a research report on Monday, March 31st. Needham & Company LLC lowered their target price on shares of Sarepta Therapeutics from $202.00 to $183.00 and set a “buy” rating for the company in a report on Thursday. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $163.00 price target on shares of Sarepta Therapeutics in a report on Tuesday, March 18th. Six equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $163.18.

Sarepta Therapeutics Stock Down 7.1 %

Shares of Sarepta Therapeutics stock opened at $54.43 on Friday. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The company has a market cap of $5.28 billion, a P/E ratio of 43.54 and a beta of 0.79. The firm’s 50 day moving average price is $96.95 and its 200-day moving average price is $113.70. Sarepta Therapeutics, Inc. has a 52-week low of $54.26 and a 52-week high of $173.25.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.